Related references
Note: Only part of the references are listed.Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal
Catherine Larochelle et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Juergen Haas et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal
Catherine Larochelle et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Juergen Haas et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Observational Study of Switching from Natalizumab to Immunomodulatory Drugs
Ramon Villaverde-Gonzalez et al.
EUROPEAN NEUROLOGY (2017)
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
Simona Malucchi et al.
NEUROLOGY AND THERAPY (2017)
Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency
S. A. Misbah
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch
Andrea Harrer et al.
CLINICAL IMMUNOLOGY (2017)
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
C. McGuigan et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
Susan Friend et al.
BMC NEUROLOGY (2016)
Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod
M. E. Evangelopoulos et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2016)
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients
Pietro Iaffaldano et al.
JOURNAL OF NEUROLOGY (2016)
Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation
Bianca Weinstock-Guttman et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Risk of relapse after natalizumab withdrawal Results from the French TYSEDMUS cohort
Caroline Papeix et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report
Francesco Patti et al.
BMC NEUROLOGY (2015)
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
Pietro Iaffaldano et al.
BRAIN (2015)
Switching from natalizumab to fingolimod A randomized, placebo-controlled study in RRMS
Ludwig Kappos et al.
NEUROLOGY (2015)
Immunosuppressive drugs and fertility
Clara Leroy et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives
Dejan Pavlovic et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study
Neda Ebrahimi et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Recurrence of disease activity after repeated Natalizumab withdrawals
Laura Ferre et al.
NEUROLOGICAL SCIENCES (2015)
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers
Marianna Lo Re et al.
NEUROLOGY AND THERAPY (2015)
Normal outcome of pregnancy with ongoing treatment with natalizumab
J. Fagius et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Tatiana Plavina et al.
ANNALS OF NEUROLOGY (2014)
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids
Silvia Rossi et al.
CNS NEUROSCIENCE & THERAPEUTICS (2014)
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients
Per Soelberg Sorensen et al.
JOURNAL OF NEUROLOGY (2014)
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
Helmut Butzkueven et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study
Paul O'Connor et al.
NEUROLOGY (2014)
Multiple Sclerosis and Pregnancy: Current Considerations
Ioan Buraga et al.
SCIENTIFIC WORLD JOURNAL (2014)
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study)
Marinella Clerico et al.
JAMA NEUROLOGY (2014)
Natalizumab Use During the Third trimester of Pregnancy
Aiden Haghikia et al.
JAMA NEUROLOGY (2014)
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients
Francesca Sangalli et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Natalizumab treatment during pregnancy - effects on the neonatal immune system
H. Schneider et al.
ACTA NEUROLOGICA SCANDINAVICA (2013)
Multiple Sclerosis: Prospects and Promise
Stephen L. Hauser et al.
ANNALS OF NEUROLOGY (2013)
Progressive multifocal leukoencephalopathy in patients with multiple sclerosis
Kelly J. Baldwin et al.
CURRENT OPINION IN NEUROLOGY (2013)
The effect of plasma exchange on serum anti-JC virus antibodies
Meena Subramanyam et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section
Joseph R. Berger et al.
NEUROLOGY (2013)
Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain
Michael W. Ferenczy et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study
G. Borriello et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
Dirk Mentzer et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
Per Soelberg Sorensen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Disease-modifying drugs for multiple sclerosis in pregnancy A systematic review
Ellen Lu et al.
NEUROLOGY (2012)
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study
F. Sangalli et al.
NEUROLOGICAL SCIENCES (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
P. W. O'Connor et al.
NEUROLOGY (2011)
Natalizumab Drug Holiday in Multiple Sclerosis: Poorly Tolerated
Joep Killestein et al.
ANNALS OF NEUROLOGY (2010)
Considerations on Discontinuing Natalizumab for the Treatment of Multiple Sclerosis
Joseph R. Berger et al.
ANNALS OF NEUROLOGY (2010)
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
Chen S. Tan et al.
LANCET NEUROLOGY (2010)
Fulminant JC Virus Encephalopathy with Productive Infection of Cortical Pyramidal Neurons
Christian Wuethrich et al.
ANNALS OF NEUROLOGY (2009)
GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
A. D. Goodman et al.
NEUROLOGY (2009)
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
B. O. Khatri et al.
NEUROLOGY (2009)
Review: Natalizumab in the treatment of multiple sclerosis
Özgür Yaldizli et al.
Therapeutic Advances in Neurological Disorders (2009)
Immune surveillance in multiple sclerosis patients treated with natalizumab
O Stüve et al.
ANNALS OF NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
BK Kleinschmidt-DeMasters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
A Langer-Gould et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Productive infection of cerebellar granule cell neurons by JC virus in an HIV plus individual
RA Du Pasquier et al.
NEUROLOGY (2003)
Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy
BF Sabath et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Share Paper
